Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Target Price at $41.67

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $41.67.

TWST has been the subject of a number of research analyst reports. Evercore ISI increased their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday. Barclays upped their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and raised their target price for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Scotiabank boosted their price target on Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,487 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the transaction, the chief executive officer now owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the sale, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the transaction, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,211 shares of company stock valued at $449,573. Company insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Artisan Partners Limited Partnership grew its stake in Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after acquiring an additional 1,961,621 shares during the period. Invesco Ltd. increased its stake in shares of Twist Bioscience by 1,496.2% during the third quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock worth $16,836,000 after purchasing an additional 778,944 shares in the last quarter. ARK Investment Management LLC raised its position in shares of Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after purchasing an additional 427,274 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc purchased a new position in Twist Bioscience in the 4th quarter valued at about $11,956,000. Finally, Norges Bank acquired a new stake in Twist Bioscience in the 4th quarter worth about $10,766,000.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $41.21 on Friday. The firm has a market cap of $2.38 billion, a PE ratio of -12.26 and a beta of 1.64. The company has a 50-day moving average of $34.03 and a 200 day moving average of $31.14. Twist Bioscience has a 1-year low of $11.81 and a 1-year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 30.81% and a negative net margin of 69.24%. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.06) EPS. Sell-side analysts anticipate that Twist Bioscience will post -3.17 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.